Navigation Links
Bioniche Responds to Australian Equine Influenza Outbreak
Date:9/6/2007

- Equimune(R) IV product a proven treatment -

BELLEVILLE, ON, Sept. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has increased its supply of Equimune(R)IV to Australia in order to be able to respond to anticipated increased demand as a result of that continent's equine influenza outbreak. The outbreak began in August, and according to one media report, a total of 3,376 horses on 405 properties are now suspected of having the virus.

"Bioniche wants to ensure that sufficient supply of Equimune IV is available to Australian veterinarians," said Jim Phillips, President of Bioniche Animal Health (global). "At the same time, we are ensuring that veterinarians have the information they require about our proprietary immunotherapy product and its efficacy in the treatment of equine influenza."

Equine influenza is a viral respiratory infection that causes flu like symptoms in horses and is from the group of viruses that causes flu in humans. Most horses exposed to the virus will show signs within a period of 1-5 days. Most viruses that are responsible for coughs and colds in horses result in mild symptoms, such as nasal discharge and coughing. Equine Influenza produces more severe symptoms, with horses developing a fever and a dry hacking cough. Horses become ill and are reluctant to eat or drink for several days, but usually recover in 2 to 3 weeks. The virus can be spread easily from horse to horse as a result of droplets and also from nasal discharge and from things like infected brushes and rugs. The disease is very contagious and there can be an almost 100% infection rate in a population that has been previously unexposed to the virus.

Australia and New Zealand are the only countries with significant equine industries that have been previously free from equine influenza. Horses in Australia are not vaccinated. Th
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Acute Gastroenteritis Responds To Treatment With Either Gatorade Or Pedialyte
2. Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat
3. Stubborn Ulcerative Colitis Responds to Arthritis Drug
4. Brain Responds Better to Name Brands
5. Australian Scientists Silence Cancer Gene
6. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
7. Australian Company Gets $10 million For Developing Skin Cancer Gel
8. World’s First Triple Transplant Performed by Australian Surgeon
9. Australian Surgeons Successfully Conduct Worlds First Triple Organ Transplant
10. Six Indians Win Australian Studies Fellowships
11. Australian Health funds stand accused
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Raleigh, NC (PRWEB) August 21, 2014 ... proteins produced by Staph bacteria has been used to ... just posted an article on the new research. ... at the University of Western Australia treated mesothelioma ... that it killed the cancer cells while simultaneously stimulating ...
(Date:8/21/2014)... Obispo, CA (PRWEB) August 21, 2014 ... of Current Pedorthics, a bi-monthly publication of the Pedorthic Footcare ... of pedorthics. , Bunion Bootie is ... alternative solution for bunion sufferers and their pain. It is ... in nearly any shoe to eliminate the friction and rubbing ...
(Date:8/21/2014)... 21, 2014 According to a recent ... Ophthalmology, environmental factors may outweigh genetics in the development and ... of the world’s population is nearsighted, and this study provides ... “This is an important finding in the field of ophthalmology,” ... are we finding better ways to treat ophthalmological conditions ...
(Date:8/21/2014)... 21, 2014 Beverly Hills Medical Center of ... to offer patients TearLab, a new diagnostic option for measuring ... eye syndrome. , “ TearLab is a revolutionary new ... can accurately measure the amount of tears a patient produces ... Dr. Ghassan Zein, Medical Director at the Kuwait medical center. ...
(Date:8/21/2014)... Beverly Hills, CA (PRWEB) August 21, 2014 ... for your overall health. Juice cleanses offer clearer skin, more ... overall immune function. Pearl Recovery Retreat, a wellness center in ... programs right from the comfort of their recovery room. ... options to get them well again following surgery in our ...
Breaking Medicine News(10 mins):Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 3
... Corporation,("WorldHeart", Nasdaq: WHRT ), a pioneer in ... Alexander ("Alex") Martin as,President and CEO. Mr. Martin ... Mr. Martin joins WorldHeart from Edwards Lifesciences where ... Vice President since,2004. Previously, Alex was with Cordis ...
... Site Uses Search to Improve Point-of-Care Decisions ... leader in enterprise search, recently published a ... Platform(TM) helps health-care practitioners deliver faster and ... The case study details Vivisimo,s application for ...
... cancer risk almost 6-fold, researchers find , , FRIDAY, Feb. ... mutations that appear to predict a significant increased risk ... to early diagnosis and treatment, the researchers said. In ... and 1,590 deaths, according to the U.S. National Cancer ...
... University at Buffalo researcher John Violanti, Ph.D., a specialist ... a study on suicide risk among returning veterans. The ... number of soldiers taking their own lives., Violanti currently ... quickly persons associate feelings of self-harm, as a way ...
... Feb. 6 Masimo Corporation (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, today announced that its management ... 21st Annual OC Growth Stock Conference at The Ritz-Carlton, ... 18, 2009, at 11:00 a.m. PT. A live audiocast ...
... Feb. 6 Optimal Reading Services Group, ... hospitals and radiology group practices, announced that its chief ... UBS Global Healthcare Services Conference on Monday, February 9, ... Hotel in New York City.Optimal leverages a deep pool ...
Cached Medicine News:Health News:WorldHeart Appoints New President and CEO 2Health News:WorldHeart Appoints New President and CEO 3Health News:New Vivisimo Case Study Details Medical Search 2Health News:Gene Test Could Predict Thyroid Cancer Risk 2Health News:Gene Test Could Predict Thyroid Cancer Risk 3Health News:Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference 2Health News:Optimal Readings to Present at 2009 UBS Global Healthcare Services Conference 2
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... available in its catalogue: Global Feminine Hygiene ... This report analyzes the worldwide markets for Feminine ... Segments: Sanitary Pads/Towels, Tampons, Panty liners, and Others. The ... Canada , Japan , ...
Breaking Medicine Technology:Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26
... (Nasdaq: VICL ),today is presenting expanded clinical ... Vaxfectin(R) adjuvant may be broadly,applicable in DNA- and ... P. Rolland, Pharm.D., Ph.D., Vical,s,Senior Vice President of ... 8, at the World Vaccine Congress (Lyon, France ...
... Texas, Oct. 7 The Texas Cardiac Arrhythmia,Institute ... selected as one of,only a few sites in ... for a new device to treat persistent atrial ... specializing in heart,rhythm disorders, is a partnership between ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: